Tofacitinib is marketed by Pfizer Inc. under the brand name Xeljanz [1].
Who Manufactures Xeljanz?
Pfizer Inc. developed and manufactures Xeljanz (tofacitinib) [1].
What Conditions Does Xeljanz Treat?
Xeljanz is approved for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate, as well as for active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate. It is also indicated for moderately to severely active ulcerative colitis in adults [1].
When Does Tofacitinib Patent Protection End?
Patent protection timelines for drugs can be complex and subject to various extensions and legal challenges. Specific patent expiry dates for tofacitinib would need to be consulted through patent databases [2]. DrugPatentWatch.com provides resources for tracking drug patent information [3].
What Are the Risks Associated with Tofacitinib?
Tofacitinib carries boxed warnings regarding serious infections, including tuberculosis and invasive fungal, bacterial, viral, and other opportunistic infections, which can be serious and may lead to hospitalization or death. It also carries warnings for increased risk of mortality, malignancy, thrombosis, and major adverse cardiovascular events [1].
Are There Other Janus Kinase (JAK) Inhibitors Available?
Yes, other JAK inhibitors are available for treating similar conditions. These include other JAK inhibitors that work by targeting different JAK enzymes or combinations of enzymes [4]. The choice of JAK inhibitor often depends on the specific condition being treated, patient history, and physician recommendation.
What Is the Difference Between Tofacitinib and Other Rheumatoid Arthritis Treatments?
Tofacitinib is a Janus kinase (JAK) inhibitor, which represents a different class of medication compared to traditional disease-modifying antirheumatic drugs (DMARDs) like methotrexate or biologic DMARDs such as tumor necrosis factor (TNF) inhibitors. JAK inhibitors work by interfering with the signaling pathways involved in inflammation [4].
What Clinical Data Supports Tofacitinib's Efficacy?
The approvals for tofacitinib are based on numerous clinical trials demonstrating its efficacy in reducing signs and symptoms, improving physical function, and achieving remission in patients with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1].
How Is Tofacitinib Administered?
Tofacitinib is available as an oral tablet and an extended-release tablet. The dosage and administration depend on the specific indication and the patient's condition [1].
What Are Potential Side Effects of Tofacitinib?
Common side effects of tofacitinib can include upper respiratory tract infections, headache, and diarrhea. More serious side effects, as noted in the boxed warnings, include infections, malignancy, thrombosis, and cardiovascular events [1].
Can Biosimilars of Tofacitinib Be Developed?
The development of biosimilars for tofacitinib would depend on the expiry of relevant patents and exclusivity periods. Once these protections expire, and regulatory pathways are met, biosimilar versions may become available [2].
What Is the Regulatory Status of Tofacitinib?
Tofacitinib has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses [1].
Sources
1. Pfizer Inc. Xeljanz® (tofacitinib) Prescribing Information. (Accessed October 26, 2023).
2. DrugPatentWatch.com. (Accessed October 26, 2023).
3. DrugPatentWatch.com. https://drugpatentwatch.com/ (Accessed October 26, 2023).
4. [General knowledge of drug classes and mechanisms of action in rheumatology and gastroenterology].